Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial

K Ke Liu B Bao-Dong Qin S Shi-Qi Chen X Xue Zhong (Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center) X Xiao-Peng Duan Y Ying Wu Z Zhan Wang Y Yan Ling L Li Sun C Chen-Yang Ye D Dong-Min Shi N Ning Gao (Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences) X Xiao-Dong Jiao Y Yuan-Sheng Zang

Article Details

Volume / Issue Vol. 16, Issue 1
Published May 31, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (14)

K

Ke Liu

B

Bao-Dong Qin

S

Shi-Qi Chen

X

Xue Zhong

Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center

X

Xiao-Peng Duan

Y

Ying Wu

Z

Zhan Wang

Y

Yan Ling

L

Li Sun

C

Chen-Yang Ye

D

Dong-Min Shi

N

Ning Gao

Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences

X

Xiao-Dong Jiao

Y

Yuan-Sheng Zang